UNSPSC 51384302: Broperamole

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H18BrN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G5MIG3753N, chemically known as piperidine, 1-(3-(5-(3-bromophenyl)-2h-tetrazol-2-yl)-1-oxopropyl)- but generally known as broperamole, which bears US NIH Compound Identifier 36341. European Medicines Agency schedules Broperamole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05927MIG.

UNSPSC 51384302 Broperamole is a Commodity code under which state and local governments procure pharmaceutical products and drug-management systems, though recent opportunities show minimal direct activity under this specific code designation. The three recent solicitations in the source reflect a broader pattern: Seminole County, Florida sought naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) established contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local jurisdictions. The mix of issuing bodies spans state health agencies, county health departments, and cooperative purchasing vehicles that serve multiple states. Work under the code includes procurement of emergency-response pharmaceuticals, generic drug supply agreements, and pharmacy benefit program administration.

Recent activity concentrates in the South and Upper Midwest, with documented solicitations in Florida, Texas, and Minnesota-led multistate purchasing. Seminole County's IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Minnesota MMCAP RFP S1070000015802, posted January 20, 2026, requested generic pharmaceuticals and OTC products from manufacturers willing to work through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; the evaluation weighted price competitiveness at 75 percent and required compliance with cGMP and Drug Supply Chain Security Act standards. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, sought vendor capabilities for a direct-to-manufacturer prescription program but functioned as preliminary market intelligence rather than a binding procurement with formal award value or timeline.